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Non-Hodgkin’s lymphoma, obesity and energy homeostasis
polymorphisms
EV Willett*,1,4, CF Skibola2,4, P Adamson1, DR Skibola2, GJ Morgan3, MT Smith2 and E Roman1
1Epidemiology and Genetics Unit, Department of Health Sciences, Seebohm Rowntree Building, University of York, York YO10 5DD, UK; 2Division of
Environmental Health Sciences, School of Public Health, 140 Earl Warren Hall, University of California, Berkeley, CA 94720-7360, USA; 3Institute of
Cancer Research, The Royal Marsden, Downs Road, Sutton, Surrey SM2 5PT, UK
A population-based case–control study of lymphomas in England collected height and weight details from 699 non-Hodgkin’s
lymphoma (NHL) cases and 914 controls. Obesity, defined as a body mass index (BMI) over 30 kg m2 at five years before diagnosis,,
was associated with an increased risk of NHL (OR¼ 1.5, 95% CI 1.1–2.1). The excess was most pronounced for diffuse large B-cell
lymphoma (OR¼ 1.9, 95% CI 1.3–2.8). Genetic variants in the leptin (LEP 19G4A, LEP 2548G4A) and leptin receptor genes
(LEPR 223Q4R), previously shown to modulate NHL risk, as well as a polymorphism in the energy regulatory gene adiponectin
(APM1 276G4T), were investigated. Findings varied with leptin genotype, the risks being decreased with LEP 19AA (OR¼ 0.7, 95%
CI 0.5–1.0) and increased with LEP 2548GA (OR¼ 1.3, 95% CI 1.0–1.7) and 2548AA (OR¼ 1.4, 95% CI 1.0–1.9), particularly
for follicular lymphoma. These genetic findings, which were independent of BMI, were stronger for men than women.
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Apart from a small proportion caused by severe immunosuppres-
sion, the cause of the majority of non-Hodgkin’s lymphomas
(NHL) remains largely unknown. Both over- and undernutrition
can suppress immunity via for example leptin, leptin receptor and
adiponectin, which are expressed by adipocytes to regulate food
intake and energy expenditure (Marti et al, 2001; Samartin and
Chandra 2001). Accordingly, it has been suggested that anthropo-
metric measures, reflecting the degree of adiposity, as well as
polymorphisms in genes associated with energy homeostasis such
as leptin (LEP), leptin receptor (LEPR) and adiponectin (APM1),
may increase NHL risk. However, while positive associations have
been reported between NHL and anthropometric characteristics
(Holly et al, 1999; Calle et al, 2003; Bahl et al, 2004; Pan et al, 2004),
others have not (Paffenbarger Jr et al, 1978; Whittemore et al,
1985; Franceschi et al, 1989; La Vecchia et al, 1990; Zhang et al,
1999; Cerhan et al, 2002; Chang et al, 2005). Furthermore,
polymorphisms in the LEP (an A to G nucleotide (nt) change at
position 19 in the 50-untranslated region (Hager et al, 1998), and a
G to A substitution at nt 2548 upstream of the ATG start site
(Mammes et al, 1998)) and LEPR (an A to G transition at nt 668
from the start codon that converts glutamine to arginine at codon
223 (223Q4R) (Gotoda et al, 1997)) genes were recently shown to
modulate NHL risk (Skibola et al, 2004).
Anthropometric and genetic findings from a large population-
based case–control study of NHL carried out in England during
the 1990s are presented here. Specifically, the potential aetiological
role of body mass index (BMI) and the polymorphisms LEP
19A4G, LEP 2548G4A, and LEPR 223Q4R, as well as a
polymorphism in the APM1 gene (a G to T substitution at nt 276
downstream of the ATG start site denoted APM1 276G4T (Hara
et al, 2002)), are investigated.
MATERIALS AND METHODS
Details of this case–control study are described elsewhere (Willett
et al, 2004). Briefly, cases were patients aged 18–64 years newly
diagnosed with lymphoma between January 1998 and March 2001.
Diagnoses were pathologically confirmed and coded to the World
Health Organisation Classification (Fritz et al, 2000), and patients
were ineligible if they had a previous diagnosis of lymphoma or
HIV. One control per case, individually matched on sex and date
of birth, was randomly selected from population registers. All
participants were interviewed in person, and asked to provide a
blood sample for research purposes. Study subjects were assigned
an area-based indicator of deprivation by coding the enumeration
districts (ED) where subjects resided at diagnosis/reference date to
categories of the 1991 census-derived Townsend scores of EDs
across England and Wales (Townsend et al, 1988). The study was
conducted with the ethical approval of the United Kingdom Multi-
Regional Ethical Committee.
At interview, participants were asked what their height and
weight was at 5, 10 and 20 years prior to diagnosis/reference date.
Body mass index was computed by dividing weight in kilograms by
the square of height in metres. Height was categorised based on
the observed distributions among controls who were aged 18 years
or over at each time point. Body mass index was grouped into
underweight (o18.5 kg m2), normal (18.5 –24.99 kg m2), grade 1
overweight (25–29.99 kg m2), and grades 2 and 3 overweight
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(30 kg m2 or more) (WHO Expert Committee on Physical Status,
1995).
DNA was isolated from peripheral blood mononuclear cells
using a modified phenol–chloroform extraction and was quanti-
fied using PicoGreens dsDNA Quantitation kits (Molecular
Probes, Eugene, OR, USA), according to the manufacturer’s
specifications. Samples, blinded to case–control status, were
genotyped using Taqmans-based assays designed by Applied
Biosystems (ABI) (Applied Biosystems, Foster City, CA, USA).
Reactions were performed on an ABI 7700 or GeneAmp PCR 9700
System for 10 min at 951C, then 40 cycles of 951C for 15 s and 601C
for 1 min; a post-PCR plate read on the ABI 7700 system was used
to determine genotype. Genotyping probes and primers used
are listed in Table 1. To ensure reproducibility of the genotyping
procedure, replicate quality control samples were included with an
agreement rate of over 99%.
Interviews were conducted with 912 lymphoma patients and 919
controls, 75% of cases and 71% of the controls identified, and
blood samples were received from 843 (94%) cases and 829 (95%)
controls who were interviewed. Among the 820 Caucasian cases
and 826 Caucasian controls who gave a blood sample, 736 (90%)
cases and 754 (91%) controls had sufficient DNA to genotype all
SNPs under investigation; insufficient or no DNA was available to
test all four SNPs for 84 (10%) cases and 72 (9%) controls. The
analysis presented here for height and BMI are restricted to 699
Caucasian cases with a confirmed diagnosis of NHL and 914
Caucasian controls, all aged 18–59 at 5 years prior to diagnosis/
reference date, while the analysis of the genotyping data includes
593 Caucasian cases with a confirmed diagnosis of NHL and 754
Caucasian controls. All analyses include controls matched to NHL
and Hodgkin’s lymphoma (HL) cases.
Odds ratios (OR) and 95% confidence intervals (CI), adjusted for
sex, age and region, were calculated using unconditional logistic
regression; risk estimates for matched analyses were also computed
using conditional logistic regression (Breslow and Day, 1980). Tests
for trend and for interaction were conducted using the likelihood
ratio test. Haplotype frequencies were estimated using log-linear
modelling embedded within an expectation maximisation algorithm.
All analyses were performed using Stata (StataCorp, 2003).
RESULTS
Among interviewed cases with a confirmed diagnosis, 317 (45%)
were diagnosed with diffuse large B-cell lymphoma (DLBCL), 228
(33%) with follicular lymphoma (FL), and 154 (22%) with rarer
forms of NHL. A higher proportion of men than women were
diagnosed with NHL and this increased with age. The majority of
controls (76%) were individually matched to cases on sex and age,
and although cases tended to be older due to the inclusion of
controls matched to patients diagnosed with Hodgkin’s lympho-
ma, there was little difference between the mean ages of cases
(53.5 years) and controls (51.8 years). Cases and controls, who
were interviewed or those who were genotyped for energy homeo-
stasis SNPs, were similar with respect to deprivation (data not shown).
Table 2 presents the height distributions of cases and controls.
Compared to those whose reported height was between 1.74 and
1.80 m, men of taller or shorter stature were not at increased risk of
NHL, DLBCL or FL. With the exception of an increased risk for
women less than 1.53 m tall (OR¼ 2.2, 95% CI 0.9– 5.1, P¼ 0.07),
no excess of NHL was observed for women who were over or under
1.58– 1.68 m tall. This elevated risk in the smallest females was
evident for DLBCL (OR¼ 2.9, 95% CI 0.9–9.0, P¼ 0.07) and not
FL, where rather, risks were decreased among women of above
average height (1.69 –1.73 m: OR¼ 0.5, 95% CI 0.3–1.0, P¼ 0.06;
41.73 m: OR¼ 0.4, 95% CI 0.2–1.0, P¼ 0.06).
Using the WHO categorisation of BMI (Table 3), risks were
estimated relative to cases and controls who were of normal
weight-for-height. Persons who were underweight were at
decreased risk (OR¼ 0.5, 95% CI 0.2–1.5, P¼ 0.22), while those
who were grade 1 overweight (OR¼ 1.2, 95% CI 1.0– 1.5, P¼ 0.10),
or grades 2 or 3 overweight (OR¼ 1.5, 95% CI 1.1–2.1, P¼ 0.01)
were at increased risk of NHL. Tests for trend were significant for
NHL and DLBCL but not for FL; a 5 kg m2 rise in BMI increasing
the risk of DLBCL by 30% (95% CI 1.2–1.5, Po0.0001). These
patterns were similar for men and women (data not shown). With
respect to age at diagnosis, there was some suggestion that the risk
of NHL associated with being markedly overweight may be more
pronounced at younger ages: the OR falling from 2.7 (95% CI 1.2–
5.8, P¼ 0.01), to 1.8 (95% CI 1.0–3.3, P¼ 0.04) to 1.2 (95% CI 0.8–
1.9, P¼ 0.42) in those aged under 45, 45–54 and 55 years or more,
respectively. Further, among the under 45 s, the finding was
stronger for DLBCL (OR¼ 3.0, 95% CI 1.2– 7.5, P¼ 0.02) than for
FL (OR¼ 1.8, 95% CI 0.5– 6.3, P¼ 0.33). Within the DLBCL
subtype, risks were greater among men aged less than 45
(OR¼ 4.7, 95% CI 1.1–19.4, P¼ 0.03 based on five cases and four
controls) than among women of the same age group (OR¼ 2.5,
95% CI 0.7–8.6, P¼ 0.15 based on five cases and 10 controls).
Analyses were repeated using anthropometric data at 10 and 20
years before diagnosis/reference date, and using the individually
Table 1 Probes and primers for LEP 19G4A, LEP 2548G4A, LEPR 223Q4R, and APM1 276G4T polymorphisms
SNP dbSNP rs number Probe/primer 50-30 sequence
LEP 19G4A rs2167270 F GGAGCCCCGTAGGAATCG
R CCAGCAGAGAAGGAGGAAGGA
A VIC-AACCGTTGGCGCTG
G 6FAM-AACCGCTGGCGCT
LEP 2548G4A rs7799039 F TCCCGTGAGAACTATTCTTCTTTTG
R CCTGCAACATCTCAGCACTTAGG
G VIC-AGGATCAGCGCAAC
A 6FAM-ATCAGTGCAACCCT
LEPR 223Q4R rs1137101 F GTTTGAAAATCACATCTGGTGGAGTA
R CATATTTATGGGCTGAACTGACATTAG
Q VIC-AGGTGACTGGAAAAT
R 6FAM-AGGTGACCGGAAAA
APM1 276G4T rs1501299 F TTTCATCACAGACCTCCTACACTGA
R TCTCCCTGTGTCTAGGCCTTAGTTA
GG VIC-TGAATGCCTTCATATAGT
T FAM-ATGAATGACTTCATATAGTT
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matched controls alone and conditional logistic regression, and the
findings were similar (data not shown).
Genotype distributions for cases and controls for the LEP
19G4A, LEP 2548G4A, LEPR 223Q4R and APM1 276G4T
polymorphisms are shown in Table 4. Control genotype distribu-
tions for all SNPs were in Hardy –Weinberg equilibrium. Relative
to LEP 19GG, the LEP 19AA genotype was inversely associated with
FL (OR¼ 0.5, 95% CI 0.3–0.8, P¼ 0.01), but not DLBCL (OR¼ 0.9,
95% CI 0.6–1.4, P¼ 0.70). For LEP 2548G4A, an increased risk
for NHL was observed among carriers of the LEP 2548GA
(OR¼ 1.3, 95% CI 1.0–1.7, P¼ 0.03) and LEP 2548AA genotypes
(OR¼ 1.4, 95% CI 1.0–1.9, P¼ 0.04), particularly for FL (LEP
2548GA: OR¼ 1.6, 95% CI 1.1–2.3, P¼ 0.01; LEP 2548AA:
OR¼ 1.4, 95% CI 0.9–2.3, P¼ 0.12) when compared to LEP
2548GG carriers. Stratifying by sex revealed that among men, the
LEP 19AA genotype was associated with a reduced risk of NHL
(OR¼ 0.6, 95% CI 0.4– 1.0, P¼ 0.06) and FL (OR¼ 0.3, 95% CI
0.1–0.7, P¼ 0.005), while the LEP 2548AA genotype was
associated with an increased risk of NHL (OR¼ 1.6, 95% CI
1.1–2.5, P¼ 0.02), DLBCL (OR¼ 1.6, 95% CI 1.0–2.7, P¼ 0.07)
and FL (OR¼ 1.8, 95% CI 0.9– 3.5, P¼ 0.10). No associations were
found in women with the exception of an increased risk of FL
among carriers of the LEP 223RR (OR¼ 1.9, 95% CI 1.0–3.6,
P¼ 0.04) relative to the LEP 223QQ genotype. There were no
differences in genotype distributions between cases and controls
for the APM1 276G4T SNP. Tests for interactions between
Table 2 Number of cases and controls, adjusted odds ratios and 95% confidence intervals for height
NHLb DLBCLb FLb
Heighta Control Case ORc 95% CI Case ORc 95% CI Case ORc 95% CI
Males 495 361 167 103
p1.65 26 19 1.0 0.5–1.9 11 1.4 0.7–3.0 4 0.7 0.2–2.1
1.66–1.73 139 103 1.0 0.7–1.4 45 1.1 0.7–1.7 32 1.0 0.6–1.7
1.74–1.80 214 151 1 — 63 1 — 47 1 —
1.81–1.88 104 82 1.1 0.8–1.6 45 1.5 0.9–2.3 19 0.8 0.5–1.5
41.88 12 6 0.7 0.3–1.9 3 0.8 0.2–3.1 1 0.4 0.0–3.0
Females 419 338 150 125
p1.52 43 35 2.2 0.9–5.1 10 2.9 0.9–9.0 19 1.1 0.4–3.5
1.53–1.57 82 74 1.1 0.6–1.9 28 1.5 0.6–3.3 34 0.9 0.5–1.8
1.58–1.68 226 171 1 — 86 1 — 55 1 —
1.69–1.73 56 38 1.0 0.6–1.6 18 1.6 0.8–3.4 11 0.5 0.3–1.0
41.73 12 20 0.9 0.5–1.6 8 1.4 0.6–3.4 6 0.4 0.2–1.0
aHeight, in metres, at diagnosis/reference date. bNHL¼ non-Hodgkin’s lymphoma; DLBCL¼ diffuse large B-cell lymphoma; FL¼ follicular lymphoma. cOdds ratios adjusted for
age and region estimated using unconditional logistic regression.
Table 3 Number of cases and controls, adjusted odds ratios and 95% confidence intervals by age for body mass index
NHLb DLBCLb FLb
BMIa Control Case ORc 95% CI Case ORc 95% CI Case ORc 95% CI
Total 914 699 317 228
Underweight 14 5 0.5 0.2–1.5 2 0.5 0.1–2.0 0 0
Normal 510 347 1 — 159 1 — 120 1 —
Grade 1 298 247 1.2 1.0–1.5 99 1.1 0.8–1.4 80 1.2 0.9–1.6
Grades 2 and 3 89 96 1.5 1.1–2.1 54 1.9 1.3–2.8 27 1.2 0.8–2.0
o45 years 202 107 60 29
Underweight 4 1 0.5 0.1–5.0 1 1.1 0.1–11.0 0
Normal 133 60 1 — 32 1 — 18 1 —
Grade 1 51 26 1.2 0.6–2.1 15 1.2 0.6–2.4 6 1.1 0.4–3.1
Grades 2 and 3 14 17 2.7 1.2–5.8 10 3.0 1.2–7.5 4 1.8 0.5–6.3
45 to o55 years 297 243 107 93
Underweight 8 1 0.2 0.0–1.3 0 0
Normal 174 127 1 — 58 1 — 49 1 —
Grade 1 91 83 1.4 0.9–2.0 32 1.1 0.7–1.9 31 1.3 0.7–2.1
Grades 2 and 3 24 31 1.8 1.0–3.3 16 2.0 1.0–4.1 13 1.9 0.9–4.0
55 to o65 years 415 349 150 106
Underweight 2 3 1.9 0.3–11.3 1 1.5 0.1–16.6 0
Normal 203 160 1 — 69 1 — 53 1 —
Grade 1 156 138 1.1 0.8–1.6 52 1.0 0.6–1.5 43 1.2 0.7–1.8
Grades 2 and 3 51 48 1.2 0.8–1.9 28 1.6 1.0–2.8 10 0.8 0.4–1.6
aBody mass index (BMI) at 5 years prior to diagnosis/reference date where BMI categorised as underweight:o18.5 kg m2; normal: 18.5 –24.99 kg m2; grade 1 overweight: 25–
29.99 kg m-2; grades 2 and 3 overweight:X30 kg m2 (WHO Expert Committee on Physical Status, 1995). BMI was missing for four cases and three controls as weight was not
reported. bNHL¼ non-Hodgkin’s lymphoma; DLBCL¼ diffuse large B-cell lymphoma; FL¼ follicular lymphoma. cOdds ratios adjusted for age, sex and region estimated using
unconditional logistic regression.
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SNPs were not statistically significant. LEP 19G4A and
LEP2548G4A among controls, with estimated haplotype frequencies
of 2548G/19A, 41.5%; 2548G/19G, 18.5%; 2548A/19G, 39.2%;
and 2548A/19A, 0.8%, were in linkage disequilibrium (D¼ 0.95),
but despite the individual SNP effects, no associations between
haplotypes and either NHL as a whole or FL in particular emerged.
Risks associated with BMI among interviewed and genotyped
subjects were similar, with the OR of NHL among the 593 cases
and 754 controls who were genotyped being 1.2 (95% CI 0.9–1.5,
P¼ 0.16) and 1.4 (95% CI 1.0–2.0, P¼ 0.08) for being grade 1 and
grades 2 or 3 overweight, respectively. To assess whether the risk
associated with the energy homeostasis polymorphisms differed
by BMI, analyses were repeated stratifying the genotyping data by
WHO categories of BMI. The risks associated with the variant
genotypes did not increase with rising grades of obesity; for
example, the risk of NHL did not incline among persons carrying
the LEP 2548AA genotype with increasing weight-for-height,
from normal weight (OR¼ 1.3, 95% CI 0.9–2.0, P¼ 0.19), through
grade 1 overweight (OR¼ 1.5, 95% CI 0.9– 2.5, P¼ 0.09), to grades
2 and 3 overweight (OR¼ 0.9, 95% CI 0.3– 2.5, P¼ 0.88). Similarly,
there was no suggestion that the risk estimates associated with the
leptin SNPs varied between persons of normal BMI, grade 1, or
grades 2 and 3 obesity (data not shown).
DISCUSSION
Here we present evidence that obesity and variants in the LEP gene
may be important in the pathogenesis of NHL. Specifically, we
found an association between NHL and excess adiposity estimated
using BMI 5 years prior to diagnosis in both men and women, with
a greater risk found among patients diagnosed at younger ages
(o45 years). Risks were elevated for the two most common NHL
subtypes, but the association remained statistically significant only
for DLBCL. In contrast, the LEP 19G4A and LEP 2548G4A
polymorphisms altered the risk of FL, particularly among men.
These SNPs were not associated with risk of DLBCL and, generally,
no associations were observed for LEPR 223Q4R and APM1
276G4T. Given the increasing obesity and lymphoma rates
worldwide, our findings may have important public health
implications.
While several studies have suggested that the risk of NHL
associated with BMI varies little with age and sex (Holly et al, 1999;
Calle et al, 2003; Pan et al, 2004; Chang et al, 2005), our study is the
first to examine risk by disease subtype, sex and age. With respect
to the former, we, like others (Cerhan et al, 2002; Skibola et al,
2004; Chang et al, 2005), found that the risk of DLBCL rose with
increasing BMI, but patterns for FL were less consistent. Non-
Hodgkin’s lymphoma, and particularly DLBCL, is more common
in men than women and the incidence increases with age above
25 years (Clarke and Glaser, 2002; Cartwright et al, 2005). Our
observation for DLBCL in young men is based on small numbers,
but if real, could reflect the effects of weight gain early in
adulthood. Not only does body fat, and hence BMI, increase with
age, but the site of fat deposition may also be important – men
being most likely to accumulate abdominal fat than women (WHO
Consultation on Obesity, 2000). Better markers of central, rather
than total, adiposity would be waist circumference or waist-to-hip
ratio (WHO Consultation on Obesity, 2000), which, up to now,
have only been reported in one study of women, but no association
with NHL was found (Cerhan et al, 2002). If weight gain in early
adulthood is not responsible, our results could instead suggest that
obesity from childhood is a risk factor for NHL. It seems unlikely
however that nutrition during childhood, linked to adult stature
(Silventoinen, 2003), increases NHL risk, since generally little
evidence of an association with height has been presented either
here or elsewhere (Whittemore et al, 1985; La Vecchia et al, 1990;
Zhang et al, 1999; Cerhan et al, 2002). Alternatively, it may be that
an underlying genetic component of obesity is involved in the
pathogenesis of NHL.
Leptin, an adipokine which circulates at levels proportional
to adipose tissue mass, regulates immune function as well as
nutritional status (Otero et al, 2005). As circulating levels increase,
leptin acts to modulate food intake, but in obesity, its rise with
Table 4 Number of cases and controls, adjusted odds ratios, and 95% confidence intervals for energy homeostasis polymorphisms
NHLa DLBCLa FLa
SNPb Control Case ORc 95% CI Case ORc 95% CI Case ORc 95% CI
Total: 754 593 270 210
LEP 19G4A
GG 275 235 1 — 104 1 — 86 1 —
AG 357 276 0.9 0.7–1.1 123 0.9 0.7–1.2 102 0.9 0.6–1.3
AA 122 79 0.7 0.5–1.0 43 0.9 0.6–1.4 20 0.5 0.3–0.8
LEP -2548G4A
GG 260 170 1 — 81 1 — 55 1 —
GA 348 294 1.3 1.0–1.7 128 1.2 0.9–1.6 113 1.6 1.1–2.3
AA 145 127 1.4 1.0–1.9 59 1.3 0.9–1.9 42 1.4 0.9–2.3
LEPR 223Q4R
QQ 234 188 1 — 88 1 — 60 1 —
QR 387 306 1.0 0.8–1.2 144 1.0 0.7–1.3 104 1.0 0.7–1.5
RR 133 99 0.9 0.7–1.3 38 0.8 0.5–1.2 46 1.3 0.8–2.0
APM1 276G4T
GG 398 341 1 — 158 1 — 114 1 —
GT 311 216 0.8 0.7–1.0 96 0.8 0.6–1.1 82 1.0 0.7–1.3
TT 45 35 0.9 0.6–1.5 16 0.9 0.5–1.6 13 1.0 0.5–2.0
aNHL¼ non-Hodgkin’s lymphoma; DLBCL¼ diffuse large B-cell lymphoma; FL¼ follicular lymphoma. bTest for Hardy–Weinberg equilibrium among controls: LEP 19G4A
w2¼ 0.12, P¼ 0.73; LEP 2548G4A w2¼ 2.17, P¼ 0.14; LEPR 223Q4R w2¼ 1.55, P¼ 0.21; APM1 276G4T w2¼ 2.41, P¼ 0.12. Samples were not amplifiable for three cases
when testing for LEP 19G4A; two cases and one control for LEP 2548G4A; and one case for APM1 276G4T. cOdds ratios adjusted for sex, age and region estimated using
unconditional logistic regression.
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increasing body fat has limited effect on satiety, suggesting
negative regulators of leptin and insulin signalling, such as leptin
receptor and adiponectin, are present (Bell et al, 2005). In the
absence of measured plasma levels before the diagnosis of NHL,
long-term variation in production of these adiponectins may be
indicated by the polymorphisms investigated here, since the
LEP 19G, LEP 2548A and LEPR 223R alleles have been associated
with elevated leptin levels, and the APM1 276T allele with lower
adiponectin levels (Hoffstedt et al, 2002; van Rossum et al, 2003;
Filippi et al, 2004). Further, these polymorphisms have been linked
with an obese phenotype in some Caucasian populations (Li et al,
1999; Mammes et al, 2000; Quinton et al, 2001; Yiannakouris et al,
2001; Nieters et al, 2002; Filippi et al, 2004; Jiang et al, 2004).
Previously, Skibola et al (2004) reported that, relative to the LEP
19AA genotype, carriers of the LEP 19G allele were at increased
risk of NHL, particularly FL (OR¼ 1.9, 95% CI 1.0–3.6). Using LEP
19GG as the referent group, the recalculated FL risk estimate for
the LEP 19AA genotype is 0.6 (95% CI 0.3–1.3), similar to the OR
of 0.5 (95% CI 0.3–0.8) presented here. As has been observed
elsewhere, the BMIs of our controls were not correlated with LEP
19G4A (r¼ 0.014, P¼ 0.70) (Karvonen et al, 1998; Lucantoni
et al, 2000), LEP 2548G4A (r¼0.013, P¼ 0.72) (Mammes
et al, 1998; Le Stunff et al, 2000), LEPR 223Q4R (r¼0.008,
P¼ 0.83) (Gotoda et al, 1997; Rosmond et al, 2000; Wauters et al,
2001) or APM1 276G4T (r¼0.024, P¼ 0.51) (Menzaghi et al,
2002; Fumeron et al, 2004). Moreover, this and the previous report
by Skibola et al found little evidence that risks associated with BMI
varied by genotype.
Obesity can induce a state of leptin and insulin resistance,
chronic low-grade inflammation, and increased leptin, tumour
necrosis factor (TNF)-a, IL-6 and C reactive protein serum levels
(Marti et al, 2001). These proinflammatory mediators can activate
a number of signalling pathways including nuclear factor (NF)-kB
that result in antiapoptotic and proliferative behaviour in B-cells.
Recently, DLBCL subtypes have been characterised by NF-kB gene
expression signatures, suggesting the significance of activation of
this transcription factor in DLBCL pathogenesis (Rosenwald and
Staudt, 2003). Increased risk of FL associated with a high leptin
producer phenotype (LEP-2548AA), or reduced risk associated
with a low leptin producer phenotype (LEP 19AA), may relate to
leptin’s action in upregulating expression of the antiapoptotic
BCL-2 protein in B-cells through the Janus kinase (JAK)/signal
transducer and activator of transcription (STAT) pathways. Most
FL have a t(14;18) chromosome translocation resulting in BCL-2
dysregulation and overexpression. Leptin also increases expression
of matrix metalloproteinases and tissue inhibitors of metallo-
proteinases, which are associated with aggressive disease, neo-
plastic growth and angiogenesis in B-cell lymphomas.
This study has a high level of case ascertainment and diagnostic
confirmation. As with all case– control studies of this type,
however, the possibility that the findings may reflect bias in the
case and/or control populations needs to be considered. In our
study, participants who resided in affluent areas were, on average,
of smaller stature and greater BMI than those who resided in
deprived areas. This pattern agrees with that seen in most national
surveys (Joint Health Surveys Unit, 2003), and it is possible that
the increased risks may have arisen from differential case– control
participation. However, adjustment for deprivation did not alter
the risk estimates for height or BMI. A further limitation relates to
the self-reported nature of the anthropometric data analysed.
Compared to a sample of the British population with anthropo-
metric measurements (National Center for Social Research, 2004),
our controls were taller and lighter, leading to a reduction in
their derived BMI. It is, however, unlikely that cases estimated
their height and weight differently from controls, as the hypothesis
that obesity is related to NHL is not widely known.
In conclusion, our findings raise the possibility that obesity may
increase risk of NHL as a whole, and DLBCL risk in particular. Our
findings were most marked among men and those diagnosed at a
comparatively young age (o45 years). Although the SNPs involved
in energy homeostasis investigated in our study did not modify
the risk of NHL associated with obesity, independent effects were
seen for FL with the LEP 19G4A and LEP 2548G4A SNPs,
irrespective of adiposity. Previous reports of NHL and BMI have
been inconsistent, with little investigation of disease subtypes.
New initiatives, aimed at pooling data from studies around the
world including the one reported here (Boffetta et al, 2003), will
hopefully provide further insight into the association between
lymphoma and BMI.
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